QUOTE
Cadence Pharmaceuticals, Inc. (CADX)
$
4.16
 -0.11 (-2.58%) Jan 26
|
12481 High Bluff Drive Suite 200,
San Diego, CA 92130,
USA
+1-858-436-1400
http://www.cadencepharm.com/ |
|
|
| PRICES |
| Open |
Volume |
| 4.29 |
730,000 |
| High |
Low |
| 4.30 |
4.05 |
|
| VALUATIONS |
| Mkt Cap |
Avg Volume |
| 263 |
90,400 |
| 52wk High |
52wk Low |
| 9.92 |
3.55 |
|
| RATIOS |
| P/E |
EPS |
| n/a |
n/a |
| BV |
P/BV |
| 1.96 |
2.12 |
|
| STOCKHOLDERS |
| Dividend |
Yield |
| n/a |
n/a |
| Shares |
Inst Owner |
| 63.11 |
|
|
|
|
|
PERFORMANCE
You need to upgrade your Flash Player
|
|
ANNUAL EARNINGS
You need to upgrade your Flash Player
|
|
QUARTERLY EARNINGS (EPS)
You need to upgrade your Flash Player
|
|
SUMMARIES CALENDARS REPORTS
|
|
| Financial Summary (In millions of USD)
|
| |
2004 | 2005 | 2006 | 2007 | 2008 | 2009 |
| Income statement |
| Total Revenue |
- | - | - | - | - | - |
| Operating Income |
$-2.80 | $-7.78 | $-53.58 | $-54.23 | $-56.53 | $-44.50 |
| Net Income |
$-2.84 | $-7.71 | $-52.17 | $-51.72 | $-57.10 | $-45.49 |
| Balance Sheet |
| Total Assets |
$4.84 | $15.89 | $93.32 | $64.61 | $55.15 | $92.56 |
| Total Equity |
$4.73 | $14.74 | $75.41 | $28.46 | $26.44 | $75.06 |
| Total Liabilities |
$0.12 | $1.15 | $17.91 | $36.15 | $28.71 | $17.50 |
| Cash Flow |
| Operating |
$-2.73 | $-6.92 | $-41.71 | $-40.68 | $-49.69 | $-42.05 |
| Investing |
$-0.57 | $-7.05 | $2.91 | $-3.38 | $-1.61 | $-8.38 |
| Financing |
$7.56 | $17.72 | $117.60 | $12.62 | $43.53 | $78.66 |
| Net Cash Change |
$4.27 | $3.75 | $78.80 | $-31.43 | $-7.77 | $28.23 |
|
Earning Call Calender
|
| 2010 | 2009 |
2008 |
2007 |
2006 |
15 March 2010
06 May 2010
05 August 2010
05 November 2010
|
12 March 2009
07 May 2009
05 August 2009
05 November 2009
|
12 March 2008
06 May 2008
07 August 2008
06 November 2008
|
13 March 2007
13 June 2007
14 August 2007
14 November 2007
|
| |
|
| Earning Call Summary |
Transcripts |
| |
|
| 10K Reports |
Annual Reports |
| |
| Ticker News
|
|
| |
Management
|
|
Executive |
Title |
|
Cam L. Garner |
Chairman of the Board | |
|
Theodore R. Schroeder |
President, Chief Executive Officer, Director |
|
William R. LaRue |
Chief Financial Officer, Senior Vice President, Treasurer |
|
James B. Breitmeyer |
Executive Vice President - Development and Chief Medical Officer |
|
Hazel M. Aker |
Senior Vice President, General Counsel, Corporate Secretary |
|
William S. Craig |
Senior Vice President - Pharmaceutical Development and Manufacturing |
|
Catherine J. Hardalo |
Vice President - Clinical Development |
|
Mike A. Royal |
Vice President - Clinical Development, Analgesics |
|
David A. Socks |
Vice President - Business Development |
|
|
|
Sources: Data collected by 123jump.com and Ticker.com from company press releases, filings and corporate websites. Market data: BATS Exchange. Inc
